Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, Minnesota 55905


Purpose:

RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of CC-4047 and to see how well it works in treating patients with myelofibrosis.


Study summary:

OBJECTIVES: Primary - To determine the maximum tolerated dose of CC-4047 in patients with primary myelofibrosis and post polycythemia vera or post essential thrombocythemia myelofibrosis. (Phase I [closed to accrual as of 12/3/2008]) - To determine the effect of this drug in these patients. (Phase II [open to accrual as of 1/7/2009]) - To determine the safety of this drug in these patients. (Phase II [open to accrual as of 1/7/2009]) Secondary - To further evaluate the nature and quality of responses to CC-4047. OUTLINE: This is a phase I dose-escalation study followed by a phase II study. - Phase I (closed to accrual as of 12/3/2008): Patients receive oral CC-4047 on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After 12 courses, patients with responding disease may continue to receive CC-4047 in the absence of disease progression or unacceptable toxicity. - Phase II (open to accrual as of 1/7/2009): Patients receive oral CC-4047 at the maximum tolerated dose determined in phase I. Patients complete quality of life questionnaires at baseline, every 28 days for the first 3 courses, and then every 3 courses (every 84 days) thereafter. After completion of study treatment, patients are followed at 28 days and then every 6 months for up to 3 years.


Criteria:

DISEASE CHARACTERISTICS: - Diagnosis of primary and post essential thrombocythemia (ET) or post polycythemia vera (PV) myelofibrosis requiring therapy - De novo presentation (i.e., agnogenic myeloid metaplasia AND post ET or post PV myelofibrosis) - Developed after an antecedent history of PV (i.e., post polycythemic myeloid metaplasia) or essential polycythemia (i.e., post thrombocythemic myeloid metaplasia) - Total hemoglobin < 10 g/dL OR transfusion dependent anemia (defined by a history of ≥ 2 units of RBC transfusions within the past 28 days for hemoglobin < 8.5 g/dL that was not associated with overt bleeding) OR marked splenomegaly (e.g., ≥ 10 cm below costal margin) PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - ANC ≥ 500/μL - Platelet count ≥ 20,000/μL - AST and ALT ≤ 3 times upper limit of normal (ULN) (≤ 5 times ULN if attributed to hepatic extramedullary hematopoiesis) - Total bilirubin ≤ 3 times ULN OR direct bilirubin ≤ 2 times ULN - Serum creatinine ≤ 2.0 mg/dL - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective double-method contraception for ≥ 28 days before, during, and for ≥ 28 days after completion of study treatment - Agrees to abstain from donating blood, semen, or sperm during and for ≥ 28 days after completion of study treatment - Willing to undergo transfusion of blood products (if applicable) - Able to complete questionnaire(s) alone or with assistance - No known HIV positivity, hepatitis B carrier, or active hepatitis C infection - No serious medical condition, psychiatric illness, or any other condition, including the presence of laboratory abnormalities, that (as judged by the treating physician) would preclude giving informed consent or participating in the study or confound the ability to interpret data from the study - No other active malignancies, except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast - No active deep vein thrombosis or pulmonary embolism that has not been therapeutically anticoagulated PRIOR CONCURRENT THERAPY: - Recovered from all prior therapy - No prior CC-4047 - More than 28 days since prior growth factors, cytotoxic chemotherapeutic agents (e.g., hydroxyurea or anagrelide), corticosteroids, or experimental drugs or therapies - No other concurrent experimental drugs or therapies or cytotoxic chemotherapeutic agents (e.g., hydroxyurea or anagrelide) for myelofibrosis - No concurrent growth factors (including erythropoietin) for myelofibrosis, except G-CSF or pegfilgrastim - No concurrent chronic use (i.e., > 2 weeks) of more than physiologic doses of corticosteroids (dose equivalent to > 10 mg/day of prednisone)


NCT ID:

NCT00669578


Primary Contact:

Principal Investigator
Ruben A. Mesa, MD
Mayo Clinic


Backup Contact:

N/A


Location Contact:

Rochester, Minnesota 55905
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 20, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.